Free Trial
NASDAQ:SCPH

scPharmaceuticals Q1 2025 Earnings Report

scPharmaceuticals logo
$2.57 +0.02 (+0.78%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$2.57 0.00 (0.00%)
As of 04/17/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

scPharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.28
Beat/Miss
N/A
One Year Ago EPS
N/A

scPharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$11.63 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

scPharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

scPharmaceuticals Earnings Headlines

Craig-Hallum Sticks to Its Buy Rating for scPharmaceuticals (SCPH)
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
scPharmaceuticals price target lowered to $12 from $20 at Maxim
Q4 2024 scPharmaceuticals Inc Earnings Call
See More scPharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like scPharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on scPharmaceuticals and other key companies, straight to your email.

About scPharmaceuticals

scPharmaceuticals (NASDAQ:SCPH), a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

View scPharmaceuticals Profile

More Earnings Resources from MarketBeat